Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients
A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer. Patients received tamoxifen 10 mg b.i.d., days 1–14, followed by medroxyprogesterone acetate 500 mg b.i.d., days 15–28, orally in an alterna...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer & clinical oncology 1987-10, Vol.23 (10), p.1451-1459 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1459 |
|---|---|
| container_issue | 10 |
| container_start_page | 1451 |
| container_title | European journal of cancer & clinical oncology |
| container_volume | 23 |
| creator | Gasparini, Giampietro Canobbio, Luciano Galligioni, Enzo Fassio, Tiziana Brema, Fulvio Crivellari, Diana Villalta, Danilo Di Fronzo, Giovanni Talamini, Renato Monfardini, Silvio |
| description | A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer.
Patients received tamoxifen 10
mg b.i.d., days 1–14, followed by medroxyprogesterone acetate 500
mg b.i.d., days 15–28, orally in an alternating sequence until progression.
Twenty-two out of 40 evaluable patients showed an objective response to treatment (55%, 95% confidence limits 38–75%). A significantly higher response rate was observed in patients with age ≥ 70 years, with soft tissue dominant lesions and with only one metastatic site. Median time to progression was 41 weeks and the median survival time 88 weeks.
In 4 cases treatment was discontinued because of severe toxicity while in the remaining patients no toxicity (20 patients) or mild side effects (17 patients) have been observed.
After 2 months of therapy, this combination showed a progestogenic effect on the endocrine parameters inducing a significant decrease of SHBG, gonadotropins, testosterone and cortisol. These preliminary clinical results and the moderate toxicity of the sequential combination support the need to further investigate this approach. |
| doi_str_mv | 10.1016/0277-5379(87)90086-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_14819924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0277537987900861</els_id><sourcerecordid>14819924</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-9bca1bc199485831a5ca38aaa8d0bb21047b00dd794365a37c8b124e0941d3593</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhbMAlVJ4A5C8QAgWae3YiR0WSKjip1IlFi1ra2JPeo0SO9hO1b4OT4rTe3WXrCx7zpwZf6eq3jB6zijrLmgjZd1y2X9Q8mNPqepq9qw6PT6_qF6m9JvSRomWn1QnTd_Rljen1d8b_LOizw4mYsI8OA_ZBU_CSDLM4cGN6Al4S3bubkdsSEhmtDE8PC4x3GHKGINHAgYzZPxEbncYYcE1O_PUht4GE12R4DiiyYk4T5aQ8ow-LLCmMhfsPXiDlgwRIWVitlskS9mkbJZeVc9HmBK-Ppxn1a9vX28vf9TXP79fXX65ro1gMtf9YIANhvW9UK3iDFoDXAGAsnQYGkaFHCi1VvaCdy1wadTAGoG0F8zytudn1fu9b_lZYZKynl0yOE3gMaxJM6GKeSOKUOyFJoaUIo56iW6G-KgZ1VsceuOuN-5aSf0Uh2al7e3Bfx0Kw2PTIYtSf3eoQzIwjbFgcOkok1yJTm7TP-9lWFjcO4w6mcKp8HOxANY2uP_v8Q-0HKy_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14819924</pqid></control><display><type>article</type><title>Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Gasparini, Giampietro ; Canobbio, Luciano ; Galligioni, Enzo ; Fassio, Tiziana ; Brema, Fulvio ; Crivellari, Diana ; Villalta, Danilo ; Di Fronzo, Giovanni ; Talamini, Renato ; Monfardini, Silvio</creator><creatorcontrib>Gasparini, Giampietro ; Canobbio, Luciano ; Galligioni, Enzo ; Fassio, Tiziana ; Brema, Fulvio ; Crivellari, Diana ; Villalta, Danilo ; Di Fronzo, Giovanni ; Talamini, Renato ; Monfardini, Silvio</creatorcontrib><description>A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer.
Patients received tamoxifen 10
mg b.i.d., days 1–14, followed by medroxyprogesterone acetate 500
mg b.i.d., days 15–28, orally in an alternating sequence until progression.
Twenty-two out of 40 evaluable patients showed an objective response to treatment (55%, 95% confidence limits 38–75%). A significantly higher response rate was observed in patients with age ≥ 70 years, with soft tissue dominant lesions and with only one metastatic site. Median time to progression was 41 weeks and the median survival time 88 weeks.
In 4 cases treatment was discontinued because of severe toxicity while in the remaining patients no toxicity (20 patients) or mild side effects (17 patients) have been observed.
After 2 months of therapy, this combination showed a progestogenic effect on the endocrine parameters inducing a significant decrease of SHBG, gonadotropins, testosterone and cortisol. These preliminary clinical results and the moderate toxicity of the sequential combination support the need to further investigate this approach.</description><identifier>ISSN: 0277-5379</identifier><identifier>DOI: 10.1016/0277-5379(87)90086-1</identifier><identifier>PMID: 2960532</identifier><identifier>CODEN: EJCODS</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Chemotherapy ; Drug Evaluation ; Female ; Hormones - blood ; Humans ; Medical sciences ; Medroxyprogesterone - administration & dosage ; Medroxyprogesterone - adverse effects ; Medroxyprogesterone - analogs & derivatives ; Medroxyprogesterone Acetate ; Menopause - blood ; Middle Aged ; Pharmacology. Drug treatments ; Prognosis ; Tamoxifen - administration & dosage ; Tamoxifen - adverse effects</subject><ispartof>European journal of cancer & clinical oncology, 1987-10, Vol.23 (10), p.1451-1459</ispartof><rights>1987</rights><rights>1988 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-9bca1bc199485831a5ca38aaa8d0bb21047b00dd794365a37c8b124e0941d3593</citedby><cites>FETCH-LOGICAL-c417t-9bca1bc199485831a5ca38aaa8d0bb21047b00dd794365a37c8b124e0941d3593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7384674$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2960532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gasparini, Giampietro</creatorcontrib><creatorcontrib>Canobbio, Luciano</creatorcontrib><creatorcontrib>Galligioni, Enzo</creatorcontrib><creatorcontrib>Fassio, Tiziana</creatorcontrib><creatorcontrib>Brema, Fulvio</creatorcontrib><creatorcontrib>Crivellari, Diana</creatorcontrib><creatorcontrib>Villalta, Danilo</creatorcontrib><creatorcontrib>Di Fronzo, Giovanni</creatorcontrib><creatorcontrib>Talamini, Renato</creatorcontrib><creatorcontrib>Monfardini, Silvio</creatorcontrib><title>Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer Clin Oncol</addtitle><description>A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer.
Patients received tamoxifen 10
mg b.i.d., days 1–14, followed by medroxyprogesterone acetate 500
mg b.i.d., days 15–28, orally in an alternating sequence until progression.
Twenty-two out of 40 evaluable patients showed an objective response to treatment (55%, 95% confidence limits 38–75%). A significantly higher response rate was observed in patients with age ≥ 70 years, with soft tissue dominant lesions and with only one metastatic site. Median time to progression was 41 weeks and the median survival time 88 weeks.
In 4 cases treatment was discontinued because of severe toxicity while in the remaining patients no toxicity (20 patients) or mild side effects (17 patients) have been observed.
After 2 months of therapy, this combination showed a progestogenic effect on the endocrine parameters inducing a significant decrease of SHBG, gonadotropins, testosterone and cortisol. These preliminary clinical results and the moderate toxicity of the sequential combination support the need to further investigate this approach.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Hormones - blood</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Medroxyprogesterone - administration & dosage</subject><subject>Medroxyprogesterone - adverse effects</subject><subject>Medroxyprogesterone - analogs & derivatives</subject><subject>Medroxyprogesterone Acetate</subject><subject>Menopause - blood</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Tamoxifen - administration & dosage</subject><subject>Tamoxifen - adverse effects</subject><issn>0277-5379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAQhbMAlVJ4A5C8QAgWae3YiR0WSKjip1IlFi1ra2JPeo0SO9hO1b4OT4rTe3WXrCx7zpwZf6eq3jB6zijrLmgjZd1y2X9Q8mNPqepq9qw6PT6_qF6m9JvSRomWn1QnTd_Rljen1d8b_LOizw4mYsI8OA_ZBU_CSDLM4cGN6Al4S3bubkdsSEhmtDE8PC4x3GHKGINHAgYzZPxEbncYYcE1O_PUht4GE12R4DiiyYk4T5aQ8ow-LLCmMhfsPXiDlgwRIWVitlskS9mkbJZeVc9HmBK-Ppxn1a9vX28vf9TXP79fXX65ro1gMtf9YIANhvW9UK3iDFoDXAGAsnQYGkaFHCi1VvaCdy1wadTAGoG0F8zytudn1fu9b_lZYZKynl0yOE3gMaxJM6GKeSOKUOyFJoaUIo56iW6G-KgZ1VsceuOuN-5aSf0Uh2al7e3Bfx0Kw2PTIYtSf3eoQzIwjbFgcOkok1yJTm7TP-9lWFjcO4w6mcKp8HOxANY2uP_v8Q-0HKy_</recordid><startdate>19871001</startdate><enddate>19871001</enddate><creator>Gasparini, Giampietro</creator><creator>Canobbio, Luciano</creator><creator>Galligioni, Enzo</creator><creator>Fassio, Tiziana</creator><creator>Brema, Fulvio</creator><creator>Crivellari, Diana</creator><creator>Villalta, Danilo</creator><creator>Di Fronzo, Giovanni</creator><creator>Talamini, Renato</creator><creator>Monfardini, Silvio</creator><general>Elsevier Ltd</general><general>Pergamon Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19871001</creationdate><title>Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients</title><author>Gasparini, Giampietro ; Canobbio, Luciano ; Galligioni, Enzo ; Fassio, Tiziana ; Brema, Fulvio ; Crivellari, Diana ; Villalta, Danilo ; Di Fronzo, Giovanni ; Talamini, Renato ; Monfardini, Silvio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-9bca1bc199485831a5ca38aaa8d0bb21047b00dd794365a37c8b124e0941d3593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Hormones - blood</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Medroxyprogesterone - administration & dosage</topic><topic>Medroxyprogesterone - adverse effects</topic><topic>Medroxyprogesterone - analogs & derivatives</topic><topic>Medroxyprogesterone Acetate</topic><topic>Menopause - blood</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Tamoxifen - administration & dosage</topic><topic>Tamoxifen - adverse effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Gasparini, Giampietro</creatorcontrib><creatorcontrib>Canobbio, Luciano</creatorcontrib><creatorcontrib>Galligioni, Enzo</creatorcontrib><creatorcontrib>Fassio, Tiziana</creatorcontrib><creatorcontrib>Brema, Fulvio</creatorcontrib><creatorcontrib>Crivellari, Diana</creatorcontrib><creatorcontrib>Villalta, Danilo</creatorcontrib><creatorcontrib>Di Fronzo, Giovanni</creatorcontrib><creatorcontrib>Talamini, Renato</creatorcontrib><creatorcontrib>Monfardini, Silvio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gasparini, Giampietro</au><au>Canobbio, Luciano</au><au>Galligioni, Enzo</au><au>Fassio, Tiziana</au><au>Brema, Fulvio</au><au>Crivellari, Diana</au><au>Villalta, Danilo</au><au>Di Fronzo, Giovanni</au><au>Talamini, Renato</au><au>Monfardini, Silvio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer Clin Oncol</addtitle><date>1987-10-01</date><risdate>1987</risdate><volume>23</volume><issue>10</issue><spage>1451</spage><epage>1459</epage><pages>1451-1459</pages><issn>0277-5379</issn><coden>EJCODS</coden><abstract>A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer.
Patients received tamoxifen 10
mg b.i.d., days 1–14, followed by medroxyprogesterone acetate 500
mg b.i.d., days 15–28, orally in an alternating sequence until progression.
Twenty-two out of 40 evaluable patients showed an objective response to treatment (55%, 95% confidence limits 38–75%). A significantly higher response rate was observed in patients with age ≥ 70 years, with soft tissue dominant lesions and with only one metastatic site. Median time to progression was 41 weeks and the median survival time 88 weeks.
In 4 cases treatment was discontinued because of severe toxicity while in the remaining patients no toxicity (20 patients) or mild side effects (17 patients) have been observed.
After 2 months of therapy, this combination showed a progestogenic effect on the endocrine parameters inducing a significant decrease of SHBG, gonadotropins, testosterone and cortisol. These preliminary clinical results and the moderate toxicity of the sequential combination support the need to further investigate this approach.</abstract><cop>Oxford</cop><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>2960532</pmid><doi>10.1016/0277-5379(87)90086-1</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-5379 |
| ispartof | European journal of cancer & clinical oncology, 1987-10, Vol.23 (10), p.1451-1459 |
| issn | 0277-5379 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_14819924 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - mortality Chemotherapy Drug Evaluation Female Hormones - blood Humans Medical sciences Medroxyprogesterone - administration & dosage Medroxyprogesterone - adverse effects Medroxyprogesterone - analogs & derivatives Medroxyprogesterone Acetate Menopause - blood Middle Aged Pharmacology. Drug treatments Prognosis Tamoxifen - administration & dosage Tamoxifen - adverse effects |
| title | Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T10%3A34%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20combination%20of%20tamoxifen%20and%20high%20dose%20medroxyprogesterone%20acetate:%20Therapeutic%20and%20endocrine%20effects%20in%20postmenopausal%20advanced%20breast%20cancer%20patients&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Gasparini,%20Giampietro&rft.date=1987-10-01&rft.volume=23&rft.issue=10&rft.spage=1451&rft.epage=1459&rft.pages=1451-1459&rft.issn=0277-5379&rft.coden=EJCODS&rft_id=info:doi/10.1016/0277-5379(87)90086-1&rft_dat=%3Cproquest_cross%3E14819924%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14819924&rft_id=info:pmid/2960532&rft_els_id=0277537987900861&rfr_iscdi=true |